

QUIDEL CORP /DE/  
Form 10-Q  
April 30, 2012  
Table of Contents

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 10-Q**

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended March 31, 2012

or

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from      to

Commission File Number: 0-10961

**QUIDEL CORPORATION**

(Exact name of Registrant as specified in its charter)

Edgar Filing: QUIDEL CORP /DE/ - Form 10-Q

**Delaware**  
(State or other jurisdiction  
of incorporation or organization)

**94-2573850**  
(I.R.S. Employer  
Identification No.)

**10165 McKellar Court, San Diego, California 92121**

(Address of principal executive offices, including zip code)

**(858) 552-1100**

(Registrant's telephone number, including area code)

**Not Applicable**

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  Accelerated filer

Non-accelerated filer  (Do not check if a smaller reporting company) Smaller reporting company

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

As of April 25, 2012, 33,086,450 shares of common stock were outstanding.

**Table of Contents**

**INDEX**

|  |    |
|--|----|
| <b><u>PART I FINANCIAL INFORMATION</u></b>   | 3  |
| <u>ITEM 1. Financial Statements (unaudited)</u>  | 3  |
| <u>Consolidated Balance Sheets as of March 31, 2012 and December 31, 2011</u>                        | 3  |
| <u>Consolidated Statements of Income for the three months ended March 31, 2012 and 2011</u>          | 4  |
| <u>Consolidated Statements of Cash Flows for the three months ended March 31, 2012 and 2011</u>      | 5  |
| <u>Notes to Consolidated Financial Statements</u>  | 6  |
| <u>ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u> | 13 |
| <u>ITEM 3. Quantitative and Qualitative Disclosures About Market Risk</u>                            | 17 |
| <u>ITEM 4. Controls and Procedures</u>   | 18 |
| <b><u>PART II OTHER INFORMATION</u></b>  | 19 |
| <u>ITEM 1. Legal Proceedings</u>   | 19 |
| <u>ITEM 1A. Risk Factors</u>   | 19 |
| <u>ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds</u>                           | 19 |
| <u>ITEM 3. Defaults Upon Senior Securities</u>   | 19 |
| <u>ITEM 4. Mine Safety Disclosures</u>   | 19 |
| <u>ITEM 5. Other Information</u>   | 19 |
| <u>ITEM 6. Exhibits</u>  | 19 |
| <u>Signatures</u>  | 21 |

**Table of Contents****PART I FINANCIAL INFORMATION****ITEM 1. Financial Statements****QUIDEL CORPORATION****CONSOLIDATED BALANCE SHEETS****(in thousands, except par value; unaudited)**

|   | March 31,<br>2012 | December 31,<br>2011 |
|---|-------------------|----------------------|
| <b>ASSETS</b>   |                   |                      |
| Current assets:   |                   |                      |
| Cash and cash equivalents   | \$ 21,555         | \$ 61,332            |
| Accounts receivable, net  | 14,447            | 14,646               |
| Inventories   | 16,206            | 14,654               |
| Deferred tax asset - current  | 10,681            | 10,681               |
| Income tax receivable   | 136               | 167                  |
| Prepaid expenses and other current assets   | 4,766             | 3,246                |
| Total current assets  | 67,791            | 104,726              |
| Property and equipment, net   | 27,757            | 28,086               |
| Goodwill  | 71,013            | 71,013               |
| Intangible assets, net  | 70,159            | 73,830               |
| Other non-current assets  | 1,310             | 1,239                |
| Total assets  | \$ 238,030        | \$ 278,894           |
| <b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>   |                   |                      |
| Current liabilities:  |                   |                      |
| Accounts payable  | \$ 6,518          | \$ 5,001             |
| Accrued payroll and related expenses  | 4,200             | 5,377                |
| Accrued royalties   | 394               | 15,093               |
| Current portion of lease obligation   | 341               | 329                  |
| Other current liabilities   | 3,804             | 7,126                |
| Total current liabilities   | 15,257            | 32,926               |
| Long term debt  | 19,000            | 42,000               |
| Lease obligation, net of current portion  | 5,857             | 5,947                |
| Deferred tax liability - non-current  | 7,041             | 7,040                |
| Income taxes payable  | 4,667             | 4,667                |
| Other non-current liabilities   | 1,096             | 928                  |
| Commitments and contingencies   |                   |                      |
| Stockholders' equity:   |                   |                      |
| Preferred stock, \$.001 par value per share; 5,000 shares authorized; none issued or outstanding at March 31, 2012 and December 31, 2011                                  |                   |                      |
| Common stock, \$.001 par value per share; 50,000 shares authorized; 33,086 and 33,276 shares issued and outstanding at March 31, 2012 and December 31, 2011, respectively | 33                | 33                   |
| Additional paid-in capital  | 174,705           | 175,030              |
| Retained earnings   | 10,374            | 10,323               |
| Total stockholders' equity  | 185,112           | 185,386              |

|   |            |            |
|---|------------|------------|
| Total liabilities and stockholders equity | \$ 238,030 | \$ 278,894 |
|---|------------|------------|

See accompanying notes.

**Table of Contents****QUIDEL CORPORATION****CONSOLIDATED STATEMENTS OF INCOME****(in thousands, except per share data; unaudited)**

|   | <b>Three months ended</b> |             |
|---|---------------------------|-------------|
|   | <b>March 31,</b>          |             |
|   | <b>2012</b>               | <b>2011</b> |
| Total revenues  | \$ 37,960                 | \$ 59,595   |
| Costs and expenses  |                           |             |
| Cost of sales (excludes amortization of intangible assets of \$1,438 and \$1,476, respectively) | 14,808                    | 20,043      |
| Research and development  | 8,504                     | 7,460       |
| Sales and marketing   | 6,536                     | 6,255       |
| General and administrative  | 5,924                     | 6,113       |
| Amortization of intangible assets from acquired businesses and technology                       | 1,718                     | 1,776       |
| Total costs and expenses  | 37,490                    | 41,647      |
| Operating income  | 470                       | 17,948      |
| Other (expense) income  |                           |             |
| Interest income   | 18                        | 52          |
| Interest expense  | (407)                     | (655)       |
| Total other expense   | (389)                     | (603)       |
| Income before taxes   | 81                        | 17,345      |
| Provision for income taxes  | 30                        | 5,897       |
| Net income  | \$ 51                     | \$ 11,448   |
| Basic and diluted earnings per share  | \$ 0.00                   | \$ 0.35     |
| Shares used in basic per share calculation  | 32,997                    | 32,451      |
| Shares used in diluted per share calculation  | 33,504                    | 32,708      |

See accompanying notes.

**Table of Contents****QUIDEL CORPORATION****CONSOLIDATED STATEMENTS OF CASH FLOWS**

(in thousands; unaudited)

|   | <b>Three months ended<br/>March 31,</b> |             |
|---|---|-------------|
|   | <b>2012</b>                             | <b>2011</b> |
| <b>OPERATING ACTIVITIES:</b>  |   |             |
| Net income  | \$ 51                                   | \$ 11,448   |
| Adjustments to reconcile net income to net cash provided by operating activities: |   |             |
| Depreciation, amortization and other  | 5,580                                   | 3,387       |
| Stock-based compensation expense  | 1,863                                   | 2,059       |
| Change in deferred tax assets and liabilities                                     | 1                                       | 5,885       |
| Changes in assets and liabilities:  |   |             |
| Accounts receivable   | 199                                     | (2,733)     |
| Inventories   | (1,552)                                 | 2,873       |
| Income tax receivable   | 31                                      | 7           |
| Prepaid expenses and other current and non-current assets                         | (1,731)                                 | (49)        |
| Accounts payable  | 1,232                                   | 21          |
| Accrued payroll and related expenses  | (1,249)                                 | 1,439       |
| Accrued royalties   | 17                                      | 2,201       |
| Accrued income taxes payable  |   | (8)         |
| Other current and non-current liabilities   | (1,656)                                 | (458)       |
| Net cash provided by operating activities   | 2,786                                   | 26,072      |
| <b>INVESTING ACTIVITIES:</b>  |   |             |
| Acquisitions of property and equipment  | (1,058)                                 | (1,026)     |
| Acquisition of intangibles  | (14,928)                                | (415)       |
| Proceeds from the sale of fixed assets  | 115                                     |             |
| Net cash used for investing activities  | (15,871)                                | (1,441)     |
| <b>FINANCING ACTIVITIES:</b>  |   |             |
| Payments on lease obligation  | (78)                                    | (67)        |
| Repurchases of common stock   | (3,387)                                 | (286)       |
| Payments on line of credit  | (23,000)                                | (30,000)    |
| Payment of note payable to state agency   | (1,498)                                 |             |
| Issuance of common stock, net of cancellations                                    | 1,271                                   | 58,558      |
| Other   |   | (686)       |
| Net cash (used for) provided by financing activities                              | (26,692)                                | 27,519      |
| Net (decrease) increase in cash and cash equivalents                              | (39,777)                                | 52,150      |
| Cash and cash equivalents, beginning of period                                    | 61,332                                  | 6,788       |
| Cash and cash equivalents, end of period  | \$ 21,555                               | \$ 58,938   |
| <b>SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</b>                         |   |             |
| Cash paid during the period for interest  | \$ 407                                  | \$ 655      |

**NON-CASH INVESTING ACTIVITIES:**

|  |        |       |
|--|--------|-------|
| Purchase of capital equipment by incurring current liabilities | \$ 285 | \$ 96 |
|--|--------|-------|

**NON-CASH FINANCING ACTIVITIES:**

|   |    |        |
|---|----|--------|
| Acquisition of other non-current assets upon issuance of common stock | \$ | \$ 478 |
|---|----|--------|

See accompanying notes.



**Table of Contents**

**Quidel Corporation**

**Notes to Consolidated Financial Statements**

**(Unaudited)**

**Note 1. Basis of Presentation**

The accompanying unaudited consolidated financial statements of Quidel Corporation and its subsidiaries (the Company) have been prepared in accordance with generally accepted accounting principles in the U.S. for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the U.S. for complete financial statements.

Certain reclassifications have been made to prior year amounts to conform to the current year presentation. The Company reclassified patent and trademark expenses of \$0.4 million from research and development expense to general and administrative expense on the Consolidated Statements of Income for the three months ended March 31, 2011. The Company reclassified stock-based compensation expense of \$0.3 million from accrued payroll and related expenses to stock-based compensation expense on the Consolidated Statements of Cash Flows for the three months ended March 31, 2011. The Company reclassified the change in other non-current assets from financing activities to operating activities of \$0.1 million on the Consolidated Statements of Cash Flows for the three months ended March 31, 2011. In the opinion of management, all adjustments considered necessary for a fair presentation (consisting of normal recurring accruals) have been included.

The information at March 31, 2012, and for the three months ended March 31, 2012 and 2011, is unaudited. Operating results for the three months ended March 31, 2012 are not necessarily indicative of the results that may be expected for the year ending December 31, 2012. For further information, refer to the Company's consolidated financial statements and footnotes thereto for the year ended December 31, 2011 included in the Company's 2011 Annual Report on Form 10-K. Subsequent events have been evaluated up to and including the date these financial statements were issued.

For 2012 and 2011, the Company's fiscal year will or has ended on December 30, 2012 and January 1, 2012, respectively. For 2012 and 2011, the Company's first quarter ended on April 1, 2012 and April 3, 2011, respectively. For ease of reference, the calendar quarter end dates are used herein. The three month periods ended March 31, 2012 and 2011 both included 13 weeks, respectively.

**Note 2. Comprehensive Income**

Net income is equal to comprehensive income for the three months ended March 31, 2012 and 2011, respectively. During the first quarter ended March 31, 2012, the Company adopted Accounting Standards Update No. 2011-05, Comprehensive Income (Topic 220): Presentation of Comprehensive Income.

**Note 3. Computation of Earnings Per Share**

Diluted net income per share is reported based on the more dilutive of the treasury stock or the two-class method. Under the two-class method, net income is allocated to common stock and participating securities. The Company's unvested restricted stock awards and certain unvested restricted stock units meet the definition of participating securities. Basic net income per share under the two-class method is computed by dividing net income adjusted for earnings allocated to unvested stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net income per share under the two-class method is computed by dividing net income adjusted for earnings allocated to unvested stockholders for the period by the weighted average number of common and common equivalent shares outstanding during the period. The Company excludes stock options from the calculation of diluted net income per share when the combined exercise price, unrecognized stock-based compensation and assumed tax benefits upon exercise are greater than the average market price for the Company's common stock because their effect is anti-dilutive. Stock options totaling 1.7 million and 2.8 million for the three months ended March 31, 2012 and 2011, respectively, were not included in the computation of diluted earnings per share ("EPS") as their effect was anti-dilutive.

**Table of Contents****Quidel Corporation****Notes to Consolidated Financial Statements****(Unaudited)****Note 3. Computation of Earnings Per Share (Continued)**

The following table sets forth the computation of basic and diluted EPS for the three months ended March 31, 2012 and 2011 (in thousands, except per share amounts):

|  | 2012    | 2011      |
|--|---------|-----------|
| Basic net income per share:                        |         |           |
| Net income   | \$ 51   | \$ 11,448 |
| Less: income allocated to participating securities |         | (113)     |
| Net income allocated to common stockholders        | \$ 51   | \$ 11,335 |
| Weighted average common shares outstanding basic   | 32,997  | 32,451    |
| Net income per share basic                         | \$ 0.00 | \$ 0.35   |
| Diluted net income per share:                      |         |           |
| Net income   | \$ 51   | \$ 11,448 |
| Less: income allocated to participating securities |         | (112)     |
| Net income allocated to common stockholders        | \$ 51   | \$ 11,336 |
| Weighted average common shares outstanding basic   | 32,997  | 32,451    |
| Dilutive securities                                | 507     | 257       |
| Weighted average common shares outstanding diluted | 33,504  | 32,708    |
| Net income per share diluted                       | \$ 0.00 | \$ 0.35   |

**Note 4. Inventories**

Inventories are recorded at the lower of cost (first-in, first-out) or market and consist of the following (in thousands):

|   | March 31,<br>2012 | December 31,<br>2011 |
|---|-------------------|----------------------|
| Raw materials                                   | \$ 5,640          | \$ 5,239             |
| Work-in-process (materials, labor and overhead) | 5,277             | 3,632                |
| Finished goods (materials, labor and overhead)  | 5,289             | 5,783                |
|   | \$ 16,206         | \$ 14,654            |



**Table of Contents****Quidel Corporation****Notes to Consolidated Financial Statements****(Unaudited)****Note 5. Other Current Liabilities**

Other current liabilities consist of the following (in thousands):

|   | March 31,<br>2012 | December 31,<br>2011 |
|---|-------------------|----------------------|
| Accrued liability for technology licenses       | \$ 890            | \$ 863               |
| Customer incentives                             | 866               | 2,352                |
| Current portion of note payable to state agency |                   | 1,498                |
| Accrued interest income taxes                   | 491               | 491                  |
| Customer prepayments                            | 207               | 202                  |
| Other   | 1,350             | 1,720                |
|   | \$ 3,804          | \$ 7,126             |

**Note 6. Income Taxes**

The Company's effective tax rate for the three months ended March 31, 2012 and 2011 was 37.0% and 34.0%, respectively. The Company recognized an income tax expense of \$30,000 and \$5.9 million for the three months ended March 31, 2012 and 2011, respectively. The difference between the March 31, 2012 and March 31, 2011 effective tax rate is primarily due to the exclusion of the federal research and development tax credit in the first quarter of 2012 due to the expiration of the statute.

The Company is subject to periodic audits by domestic and foreign tax authorities. The Company's federal tax years for 1995 and forward are subject to examination by the U.S. authorities due to the carry forward of unused net operating losses and research and development credits. With few exceptions, the Company's tax years for 1999 and forward are subject to examination by state and foreign tax authorities. The Company believes that it has appropriate support for the income tax positions taken on its tax returns and that its accruals for tax liabilities are adequate for all open years based on an assessment of many factors, including past experience and interpretations of tax law applied to the facts of each matter.

**Note 7. Line of Credit**

The Company currently has a \$120.0 million senior secured syndicated credit facility (the "Senior Credit Facility"), which matures on October 8, 2013. The Senior Credit Facility bears interest at the lower of either the Eurodollar rate or base rate. The Eurodollar rate is equal to the Eurodollar rate plus the applicable rate, and the base rate is equal to the higher of the federal funds rate plus one-half of one percent plus the applicable rate, or the lenders prime rate. The applicable rate is generally determined in accordance with a performance pricing grid based on the Company's leverage ratio and ranges from 1.50% to 2.75% for Eurodollar rate loans and from 0.50% to 1.75% for base rate loans (weighted average interest rate of 1.99% at March 31, 2012). The agreement governing the Senior Credit Facility is subject to certain customary limitations, including among others: limitation on liens; limitation on mergers, consolidations and sales of assets; limitation on debt; limitation on dividends, stock redemptions and the redemption and/or prepayment of other debt; limitation on investments (including loans and advances) and acquisitions; limitation on transactions with affiliates; and limitation on annual capital expenditures. The Company is also subject to financial covenants which include a funded debt to adjusted EBITDA ratio (as defined in the Senior Credit Facility, with adjusted EBITDA generally calculated as earnings before, among other adjustments, interest, taxes, depreciation and amortization) not to exceed 3 to 1 as of the end of each fiscal quarter, and an interest coverage ratio of not less than 3.5 to 1 as of the end of each fiscal quarter. The Senior Credit Facility is secured by substantially all present and future assets and properties of the Company. As of March 31, 2012, the Company had \$53.5 million available under the Senior Credit Facility. The Company's ability to borrow under the Senior Credit Facility fluctuates from time to time due to, among other factors, the Company's borrowings under the facility and its funded debt to adjusted EBITDA ratio. As of March 31, 2012, the

## Edgar Filing: QUIDEL CORP /DE/ - Form 10-Q

Company had \$19.0 million outstanding under the Senior Credit Facility. As of March 31, 2012, the Company was in compliance with all financial covenants.

**Table of Contents****Quidel Corporation****Notes to Consolidated Financial Statements****(Unaudited)****Note 8. Stockholders' Equity**

During the three months ended March 31, 2012, 99,850 shares of restricted stock were awarded, 219 shares of restricted stock were cancelled, 18,620 shares of common stock were issued due to the exercise of stock options and 23,442 shares of common stock were issued in connection with the Company's employee stock purchase plan (the ESPP), resulting in net proceeds to the Company of approximately \$1.3 million. Additionally, during the three months ended March 31, 2012, 231,704 shares of outstanding common stock were repurchased for approximately \$3.4 million, which primarily included shares repurchased under the Company's previously announced share repurchase program, but also included 31,304 shares repurchased in connection with payment of minimum tax withholding obligations for certain employees relating to the lapse of restrictions on certain restricted stock awards during the three months ended March 31, 2012. At March 31, 2012, the Company had \$22.1 million available for repurchases under the Company's previously announced share repurchase program.

**Note 9. Stock-Based Compensation**

The compensation expense related to the Company's stock-based compensation plans included in the accompanying Consolidated Statements of Income for the three months ended March 31, 2012 and 2011 was as follows (in millions):

|                            | Three months<br>ended<br>March 31, |        |
|----------------------------|------------------------------------|--------|
|                            | 2012                               | 2011   |
| Cost of sales              | \$ 0.1                             | \$ 0.2 |
| Research and development   | 0.3                                | 0.2    |
| Sales and marketing        | 0.1                                | 0.1    |
| General and administrative | 1.4                                | 1.6    |
|                            | \$ 1.9                             | \$ 2.1 |

Total compensation expense recognized for the three months ended March 31, 2012 and 2011 includes \$1.0 million and \$1.4 million related to stock options and \$0.9 million and \$0.7 million related to restricted stock, respectively. As of March 31, 2012, total unrecognized compensation expense related to non-vested stock options was \$6.5 million, which is expected to be recognized over a weighted-average period of approximately 2.5 years. As of March 31, 2012, total unrecognized compensation expense related to non-vested restricted stock was \$2.4 million, which is expected to be recognized over a weighted-average period of approximately 2.1 years. Compensation expense capitalized to inventory and compensation expense related to the Company's ESPP were not material for the three months ended March 31, 2012 and 2011.

The estimated fair value of each stock option award was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions for the option grants.

|                                 | Three months<br>ended<br>March 31, |       |
|---------------------------------|------------------------------------|-------|
|                                 | 2012                               | 2011  |
| Expected option life (in years) | 5.51                               | 5.21  |
| Volatility rate                 | 0.46                               | 0.47  |
| Risk-free interest rate         | 0.84%                              | 2.16% |

## Edgar Filing: QUIDEL CORP /DE/ - Form 10-Q

Dividend rate

0%

0%

The weighted-average grant date fair value of stock options granted during the three months ended March 31, 2012 and 2011 was \$6.49 and \$5.61, respectively. The Company granted 572,466 and 425,668 stock options during the three months ended March 31, 2012 and 2011, respectively. The weighted-average grant date fair value of restricted stock granted during the three months ended March 31, 2012 and 2011 was \$15.27 and \$12.99, respectively. The Company granted 99,850 and 163,695 shares of restricted stock during the three months ended March 31, 2012 and 2011, respectively. The grant date fair value of restricted stock is determined based on the closing market price of the Company's common stock on the grant date.

**Table of Contents****Quidel Corporation****Notes to Consolidated Financial Statements****(Unaudited)****Note 10. Industry and Geographic Information**

The Company operates in one reportable segment. Sales to customers outside the U.S. represented \$5.5 million (15%) and \$5.3 million (9%) of total revenue for the three months ended March 31, 2012 and 2011, respectively. As of March 31, 2012 and December 31, 2011, balances due from foreign customers were \$2.4 million and \$4.8 million, respectively.

The Company had sales to individual customers in excess of 10% of total revenue, as follows:

|           | Three months ended |      |
|-----------|--------------------|------|
|           | March 31,          |      |
|           | 2012               | 2011 |
| Customer: |                    |      |
| A         | 17%                | 17%  |
| B         | 4%                 | 15%  |
|           | 21%                | 32%  |

As of March 31, 2012, accounts receivable from customers with balances due in excess of 10% of total accounts receivable totaled \$3.7 million while, at December 31, 2011, accounts receivable from customers with balances due in excess of 10% of total accounts receivable totaled \$5.5 million.

**Note 11. Commitments and Contingencies****Licensing Arrangements**

On September 27, 2011, the Company entered into the Second Amendment (the *Amendment*) to Quidel/Inverness Settlement Agreement dated April 27, 2005 (the *Agreement*), as amended by an addendum dated June 19, 2006, with Alere Inc. (formerly known as Inverness Medical Innovations, Inc.) (*Alere*).

The Amendment, which was effective as of April 1, 2011, amended certain royalty and other provisions in the Agreement and enabled the Company to "buy-down" and "buy-out" its future royalty obligation under the Agreement for payments totaling \$29.5 million. Under the Amendment, the Company made an initial cash payment of \$13.8 million to Alere in September 2011 in connection with a buy-down of the Company's royalty obligations for the period beginning July 1, 2011. In addition, the Company exercised its buy-out right for any remaining future royalty obligation by exercising the Royalty Termination Option (as defined in the Amendment) in January 2012, thereby terminating the Company's obligation to pay future royalties under the Agreement in exchange for a fixed cash payment in the amount of \$15.7 million less \$1.0 million of specified third quarter 2011 royalties. This amount was paid in February 2012.

In conjunction with Financial Accountings Standards Board Accounting Standard Update No. 2009-05, *Fair Value Measurements and Disclosures (Topic 820)*, the Company assigned \$28.8 million to the licensed technology and \$0.7 million as a one-time charge to cost of sales. In determining the fair value allocation between the intangible asset licensed technology and the one-time charge to cost of sales, the Company assessed the past and estimated future revenue streams related to present and future products that use the patents that are subject to the Amendment. The effective life and related amortization of the licensed technology will be based on the higher of the percentage of usage or the straight-line method. This percentage of usage will be determined using the revenues generated from products covered by the patents that are subject to the Amendment. The terms of the Amendment provide for an estimated useful life of 3.5 years for this asset. The Company recorded



\$2.1 million of amortization expense included as a portion of cost of sales in the three months ended March 31, 2012.

---

**Table of Contents**

**Quidel Corporation**

**Notes to Consolidated Financial Statements**

**(Unaudited)**

**Note 11. Commitments and Contingencies (Continued)**

The Company has entered into various other licensing agreements, which largely require royalty payments based on specified product sales as well as the achievement of specified milestones.

**Legal**

The Company is involved in various claims and litigation matters from time to time in the ordinary course of business. Management believes that all such current legal actions, in the aggregate, will not have a material adverse effect on the Company. The Company also maintains insurance, including coverage for product liability claims, in amounts which management believes are appropriate given the nature of its business. At March 31, 2012, the Company had \$0.5 million accrued in other current liabilities and \$0.3 million accrued in other non-current liabilities for various legal matters where the Company deemed the liability probable and estimable.

**Note 12. Lease Obligation**

During 1999, the Company completed a sale and leaseback transaction of its San Diego facility. The facility was sold for \$15.0 million, of which \$3.8 million was capital contributed by the Company. The sale was an all cash transaction, netting the Company approximately \$7.0 million. The Company is a 25% limited partner in the partnership that acquired the facility. The transaction was deemed a financing transaction under the guidance in ASC Topic 840-40, Accounting for Sales of Real Estate. The assets sold remain on the books of the Company and will continue to be depreciated over the estimated useful life. In December 2009, the Company amended the terms of its lease agreement which had no significant impact on the Company's financial statements. The amended terms include a new ten-year lease term through December 2019, with options to extend the lease for up to three additional five-year periods. The Company will amortize the lease obligation over this new term. The amount of the monthly rental payments remain the same under the amendment. In addition, the Company has the option to purchase the general partner's interest in the partnership in January 2015 for a fixed price. The Company has determined that the partnership is a variable interest entity (VIE). The Company is not, however, the primary beneficiary of the VIE as it does not absorb the majority of the partnership's expected losses or receive a majority of the partnership's residual returns. The Company made lease payments to the partnership of approximately \$0.3 million for each of the three months ended March 31, 2012 and 2011.

**Note 13. Fair Value Measurement**

*ASC Topic 820, Fair Value Measurements and Disclosures* requires the valuation of assets and liabilities subject to fair value measurements using a three tiered approach and fair value measurement be classified and disclosed by the Company in one of the following three categories:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability;

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).

**Table of Contents**

**Quidel Corporation**

**Notes to Consolidated Financial Statements**

**(Unaudited)**

**Note 13. Fair Value Measurement (Continued)**

As of March 31, 2012 and December 31, 2011, the carrying amount of the Company's Senior Credit Facility approximates fair value because it has a variable interest rate that reflects market changes to interest rates and changes in the Company's leverage ratio. As of March 31, 2012 and December 31, 2011, the Company used Level 2 inputs to determine the fair value of its Senior Credit Facility. As of March 31, 2012 and December 31, 2011, the carrying amount of the Company's cash equivalents approximates fair value. Cash equivalents primarily consisted of funds held in a money market account. As of March 31, 2012 and December 31, 2011, fair value was determined based on Level 1 inputs.

---

**Table of Contents**

**ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

In this quarterly report, all references to we, our and us refer to Quidel Corporation and its subsidiaries.

**Future Uncertainties and Forward-Looking Statements**

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the federal securities laws that involve material risks, assumptions and uncertainties. Many possible events or factors could affect our future financial results and performance, such that our actual results and performance may differ materially from those that may be described or implied in the forward-looking statements. As such no forward-looking statement can be guaranteed. Differences in actual results and performance may arise as a result of a number of factors including, without limitation, seasonality, the timing of onset, length and severity of cold and flu seasons, the level of success in executing on our strategic initiatives, our reliance on sales of our influenza diagnostic tests, uncertainty surrounding the detection of novel influenza viruses involving human specimens, our ability to develop new products and technology, adverse changes in the competitive and economic conditions in domestic and international markets, our reliance on and actions of our major distributors, technological changes and uncertainty with research and technology development, including any future molecular-based technology, the medical reimbursement system currently in place and future changes to that system, manufacturing and production delays or difficulties, adverse regulatory actions or delays in product reviews by the U.S. Food and Drug Administration (the FDA), compliance with FDA and environmental regulations, our ability to meet unexpected increases in demand for our products, our ability to execute our growth strategy, including the integration of new companies or technologies, disruptions in the global capital and credit markets, our ability to hire key personnel, intellectual property, product liability, environmental or other litigation, potential required patent license fee payments not currently reflected in our costs, potential inadequacy of booked reserves and possible impairment of goodwill, and lower than anticipated acceptance, sales or market penetration of our new products. Forward-looking statements typically are identified by the use of terms such as may, will, should, might, expect, anticipate, estimate, and similar words, although some forward-looking statements are expressed differently. Forward-looking statements in this Quarterly Report include, among others, statements concerning: our outlook for the upcoming fiscal year, including projections about our revenue, gross margins, expenses, and the effect the DHI acquisition will have on the seasonality of our business; projected capital expenditures for the upcoming fiscal year and our source of funds for such expenditures; the sufficiency of our liquidity and capital resources; the future impact of deferred tax assets or liabilities; the expected vesting periods of unrecognized compensation expense; and our intention to maintain our emphasis on research and development and continue to evaluate technology and Company acquisition opportunities and the source of funds for such investments. The risks described under Risk Factors in Item 1A of this Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2011, and elsewhere herein and in reports and registration statements that we file with the Securities and Exchange Commission (the SEC) from time to time, should be carefully considered. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date of this Quarterly Report. The following should be read in conjunction with the audited Consolidated Financial Statements and Notes thereto beginning on page 3 of this Quarterly Report. We undertake no obligation to publicly release the results of any revision or update of these forward-looking statements, except as required by law.

**Overview**

We have a leadership position in the development, manufacturing and marketing of rapid diagnostic testing solutions. These diagnostic testing solutions primarily include applications in infectious diseases, women's health and gastrointestinal diseases. We sell our products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail clinics and wellness screening centers. We market our products in the U.S. through a network of national and regional distributors, and a direct sales force. Internationally, we sell and market primarily in Japan and Europe through distributor arrangements.

**Table of Contents****Outlook**

We anticipate revenue growth over the next nine months as compared to the same nine month period in the prior year and a related positive impact on gross margin and net earnings. We will continue our focus on prudently managing our business and delivering solid financial results, while at the same time striving to continue to introduce new products to the market and maintaining our emphasis on research and development investments for longer term growth. Finally, we will continue to evaluate opportunities to acquire new product lines and technologies, as well as, company acquisitions.

**Results of Operations****Three months ended March 31, 2012 compared to the three months ended March 31, 2011****Total Revenues**

The following table compares total revenues for the three months ended March 31, 2012 and 2011 (in thousands, except percentages):

|  | For the three months ended March 31, |           | Increase (Decrease) |       |
|--|--------------------------------------|-----------|---------------------|-------|
|  | 2012                                 | 2011      | \$                  | %     |
| Infectious disease net product sales       | \$ 26,354                            | \$ 47,650 | \$ (21,296)         | (45)% |
| Women's health net product sales           | 8,259                                | 7,985     | 274                 | 3%    |
| Gastrointestinal disease net product sales | 1,610                                | 1,719     | (109)               | (6)%  |
| Other net product sales                    | 1,301                                | 1,590     | (289)               | (18)% |
| Royalty, license fees and grant revenue    | 436                                  | 651       | (215)               | (33)% |
| Total revenues                             | \$ 37,960                            | \$ 59,595 | \$ (21,635)         | (36)% |

The decrease in total revenues was largely related to a weak 2011/2012 cold and flu season. This had an adverse impact on our infectious disease products, including influenza, Group A Strep, RSV and DFA respiratory. Revenues in other product categories remained relatively constant period over period.

The revenue from our royalty, license fees and grant revenue category for all periods primarily relates to royalty payments earned on our patented technologies utilized by third parties.

**Cost of Sales**

Cost of sales was \$14.8 million, or 39% of total revenues for the three months ended March 31, 2012, compared to \$20.0 million, or 34% of total revenues for the three months ended March 31, 2011. The absolute dollar decrease in cost of sales is primarily related to the variable nature of direct costs (material and labor) associated with the 36% decrease in total revenues. The increase in cost of sales as a percentage of total revenues is primarily driven by a shift in product mix as flu volume was lower in the first quarter of 2012 compared to 2011.

**Operating Expenses**

The following table compares operating expenses for the three months ended March 31, 2012 and 2011 (in thousands, except percentages):

**Table of Contents**

|   | For the three months ended March 31, |                          |                    |                          | Increase (Decrease) |      |
|---|--------------------------------------|--------------------------|--------------------|--------------------------|---------------------|------|
|   | 2012                                 |                          | 2011               |                          | \$                  | %    |
|   | Operating expenses                   | As a % of total revenues | Operating expenses | As a % of total revenues |                     |      |
| Research and development  | \$ 8,504                             | 22%                      | \$ 7,460           | 13%                      | \$ 1,044            | 14%  |
| Sales and marketing   | 6,536                                | 17%                      | 6,255              | 10%                      | 281                 | 4%   |
| General and administrative  | 5,924                                | 16%                      | 6,113              | 10%                      | (189)               | (3)% |
| Amortization of intangible assets from acquired businesses and technology | 1,718                                | 5%                       | 1,776              | 3%                       | (58)                | %    |
| <b>Research and Development Expense</b>                                   |                                      |                          |                    |                          |                     |      |

Research and development expense increased primarily due to the timing of costs associated with our clinical studies and a project milestone payment for the three months ended March 31, 2012. Other key components of this expense relate to personnel, consulting and laboratory supplies.

**Sales and Marketing Expense**

Sales and marketing expense increased slightly due to additional investments in our sales organization, including an increase in headcount and corresponding training costs that occurred towards the latter part of the first quarter ended March 31, 2012. Other key components of this expense relate to continued investment in existing products and customer marketing programs.

**General and Administrative Expense**

The decrease in general and administrative expenses is primarily due to a decrease in the incentive compensation accrual for the three months ended March 31, 2012 related to the decrease in total revenues and earnings.

**Amortization of Intangible Assets from Acquired Businesses and Technology**

Amortization of intangible assets from acquired businesses and technology consists primarily of customer relationships, purchased technology and patents and trademarks acquired in connection with our acquisition of DHI.

**Other Income (Expense)**

The decrease in interest expense is related to a decrease in the average debt outstanding under our Senior Credit Facility for the three months ended March 31, 2012 as compared to the three months ended March 31, 2011. Interest expense primarily relates to interest paid on borrowings under the Senior Credit Facility and interest paid on our lease obligation associated with our San Diego facility.

**Income Taxes**

Our effective tax rate for the three months ended March 31, 2012 and 2011 was 37.0% and 34.0%, respectively. We recognized an income tax expense of \$30,000 and \$5.9 million for the three months ended March 31, 2012 and 2011, respectively. The difference between the March 31, 2012 and March 31, 2011 effective tax rate is primarily due to the exclusion of the federal research and development tax credit in the first quarter of 2012 due to the expiration of the statute.

**Liquidity and Capital Resources**

As of March 31, 2012, our principal sources of liquidity consisted of \$21.6 million in cash and cash equivalents, as well as \$53.5 million available to us under our Senior Credit Facility. Our working capital as of March 31, 2012 was \$52.5 million.

---

**Table of Contents**

Cash provided by operating activities was \$2.8 million during the three months ended March 31, 2012. We had net income of \$51,000, including non-cash charges of \$7.4 million of depreciation and amortization of intangible assets and property and equipment, and stock-based compensation.

Our investing activities used \$15.9 million during the three months ended March 31, 2012 primarily related to the acquisition of intangibles associated with our exercise of a buyout clause under the Alere Amendment. During the three months ended March 31, 2012, we exercised the buy-out right under the Alere Amendment, which allowed us to buy-out any remaining future royalty obligation for a fixed cash payment in the amount of \$15.7 million less \$1.0 million of specified third quarter 2011 royalties. In addition, we used cash for investing activities associated with the acquisition of production and scientific equipment, and building improvements during the three months ended March 31, 2012.

We are planning approximately \$10.0 million in capital expenditures for the remainder of 2012. The primary purpose for our capital expenditures is to acquire manufacturing and scientific equipment, implement facility improvements, and for the purchase or development of information technology. We plan to fund these capital expenditures with cash flow from operations and other available sources of liquidity. We have \$1.2 million in firm purchase commitments with respect to such planned capital expenditures as of the date of filing this report.

Cash used for financing activities of \$26.7 million was primarily related to repayments under our Senior Credit Facility of \$23.0 million, and repurchases of 200,400 shares of our common stock under our share repurchase program at a cost of approximately \$2.9 million.

We currently have a \$120.0 million Senior Credit Facility, which matures on October 8, 2013. The Senior Credit Facility bears interest at the lower of either the Eurodollar rate or base rate. The Eurodollar rate is equal to the Eurodollar rate plus the applicable rate, and the base rate is equal to the higher of the federal funds rate plus one-half of one percent plus the applicable rate, or the lenders prime rate. The applicable rate is generally determined in accordance with a performance pricing grid based on our leverage ratio and ranges from 1.50% to 2.75% for Eurodollar rate loans and from 0.50% to 1.75% for base rate loans (weighted average interest rate of 1.99% at March 31, 2012). The agreement governing the Senior Credit Facility is subject to certain customary limitations, including among others: limitation on liens; limitation on mergers, consolidations and sales of assets; limitation on debt; limitation on dividends, stock redemptions and the redemption and/or prepayment of other debt; limitation on investments (including loans and advances) and acquisitions; limitation on transactions with affiliates; and limitation on annual capital expenditures. We are also subject to financial covenants which include a funded debt to adjusted EBITDA ratio (as defined in the Senior Credit Facility, with adjusted EBITDA generally calculated as earnings before, among other adjustments, interest, taxes, depreciation and amortization) not to exceed 3 to 1 as of the end of each fiscal quarter, and an interest coverage ratio of not less than 3.5 to 1 as of the end of each fiscal quarter. The Senior Credit Facility is secured by substantially all of our present and future assets and properties. As of March 31, 2012, we had \$53.5 million available under the Senior Credit Facility. Our ability to borrow under the Senior Credit Facility fluctuates from time to time due to, among other factors, our borrowings under the facility and our funded debt to adjusted EBITDA ratio. As of March 31, 2012, we had \$19.0 million outstanding under the Senior Credit Facility. As of March 31, 2012, we were in compliance with all financial covenants.

Our cash requirements fluctuate as a result of numerous factors, such as the extent to which we generate cash from operations, progress in research and development projects, competition and technological developments and the time and expenditures required to obtain governmental approval of our products. In addition, we intend to continue to evaluate candidates for acquisitions or technology licensing. If we determine to proceed with any such transactions, we may need to incur additional debt, or issue additional equity, to successfully complete the transactions. Based on our current cash position and our current assessment of future operating results, we believe that our existing sources of liquidity will be adequate to meet our operating needs during the next 12 months.

**Off-Balance Sheet Arrangements**

At March 31, 2012, we did not have any relationships or other arrangements with unconsolidated entities or financial partners, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. As such, we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships.

---

## **Table of Contents**

### **New Accounting Standards**

In June 2011, the Financial Accounting Standards Board ( FASB ) issued Accounting Standards Update ( ASU ) No. 2011-05, *Comprehensive Income (Topic 220): Presentation of Comprehensive Income* ( ASU 2011-05 ). The provisions of this ASU amend FASB Accounting Standards Codification ( ASC ) Topic 220, Comprehensive Income, to facilitate the continued alignment of U.S. GAAP with International Accounting Standards. ASU 2011-05 prohibits the presentation of the components of comprehensive income in the statement of stockholders' equity. Reporting entities are allowed to present either: a statement of comprehensive income, which reports both net income and other comprehensive income; or separate, but consecutive, statements of net income and other comprehensive income. Under previous GAAP, all three presentations were acceptable. Regardless of the presentation selected, the Reporting Entity is required to present all reclassifications between other comprehensive and net income on the face of the new statement or statements. The provisions of this ASU are effective for us for fiscal years and interim periods beginning after December 31, 2011 and the required presentation is included in this filing.

In September 2011, the FASB issued ASU No. 2011-08, *Intangibles - Goodwill and Other (Topic 350): Testing Goodwill for Impairment* ( ASU 2011-08 ), to allow entities to use a qualitative approach to test goodwill for impairment. ASU 2011-08 permits an entity to first perform a qualitative assessment to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. If it is concluded that this is the case, it is necessary to perform the currently prescribed two-step goodwill impairment test. Otherwise, the two-step goodwill impairment test is not required. ASU 2011-08 is effective for us beginning in fiscal year 2013, however, earlier adoption is permitted. We are currently evaluating the impact of our pending adoption of ASU 2011-08 on our consolidated financial statements.

### **Critical Accounting Policies and Estimates**

Our discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including those related to revenue recognition; stock-based compensation; reserve for uncollectible accounts; inventory valuation; intangible assets; software development costs; and income taxes. We base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

A comprehensive discussion of our critical accounting policies and management estimates is included in Management's Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2011.

### **ITEM 3. Quantitative and Qualitative Disclosures About Market Risk**

#### *Interest Rate Risk*

The fair market value of our floating interest rate debt is subject to interest rate risk. Generally, the fair market value of floating interest rate debt will vary as interest rates increase or decrease. We had \$19.0 million outstanding under our Senior Credit Facility at March 31, 2012. The weighted average interest rate on these borrowings is currently 1.99%. A hypothetical 100 basis point adverse move in interest rates along the entire interest rate yield curve would increase our annual interest expense by approximately \$0.2 million. Based on our market risk sensitive instruments outstanding at March 31, 2012, we have determined that there was no material market risk exposure from such instruments to our consolidated financial position, results of operations or cash flows as of such date.

Our current investment policy with respect to our cash and cash equivalents focuses on maintaining acceptable levels of interest rate risk and liquidity. Although we continually evaluate our placement of investments, as of March 31, 2012, our cash and cash equivalents were placed in money market or overnight funds that we believe are highly liquid and not subject to material market fluctuation risk.



**Table of Contents**

*Foreign Currency Exchange Risk*

The majority of our international sales are negotiated for and paid in U.S. dollars. Nonetheless, these sales are subject to currency risks, since changes in the values of foreign currencies relative to the value of the U.S. dollar can render our products comparatively more expensive. These exchange rate fluctuations could negatively impact international sales of our products, as could changes in the general economic conditions in those markets. Continued change in the values of the Euro, the Japanese Yen and other foreign currencies could have a negative impact on our business, financial condition and results of operations. We do not currently hedge against exchange rate fluctuations, which means that we are fully exposed to exchange rate changes. In addition, we have a supply agreement with a foreign vendor whereby we evenly share the foreign currency exchange fluctuation risk. We may, in the future, enter into similar such arrangements.

**ITEM 4. Controls and Procedures**

*Evaluation of disclosure controls and procedures:* We have performed an evaluation under the supervision and with the participation of our management, including our Chief Executive Officer ( CEO ) and Chief Financial Officer ( CFO ), of the effectiveness of our disclosure controls and procedures, as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the Exchange Act ). Based on that evaluation, our CEO and CFO concluded that our disclosure controls and procedures were effective as of March 31, 2012 to provide reasonable assurance that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC s rules and forms.

*Changes in internal control over financial reporting:* There was no change in our internal control over financial reporting during the quarter ended March 31, 2012 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

**Table of Contents****PART II OTHER INFORMATION****ITEM 1. Legal Proceedings**

We are involved in various claims and litigation matters from time to time in the ordinary course of business. We believe that all such current legal actions, in the aggregate, will not have a material adverse effect on the company. We also maintain insurance, including coverage for product liability claims, in amounts which we believe are appropriate given the nature of the business.

**ITEM 1A. Risk Factors**

There has been no material change in our risk factors as previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2011. For a detailed description of our risk factors, refer to Item 1A, Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2011.

**ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds**

The table below sets forth information regarding repurchases of our common stock by us during the three months ended March 31, 2012:

| Period   | Total number of shares purchased(1) | Average price paid per share | Total number of shares purchased as part of publicly announced plans or programs | Approximate dollar value of shares that may yet be purchased under the plans or programs (2) |
|----------|-------------------------------------|------------------------------|--|--|
| January  | 96,141                              | \$ 14.91                     | 74,000   | \$ 23,902,000  |
| February | 135,563                             | 14.41                        | 126,400  | 22,081,000   |
| March    |                                     |                              |  | 22,081,000   |
| Total    | 231,704                             | \$ 14.62                     | 200,400  | \$ 22,081,000  |

- (1) In addition to our share repurchase program, we withheld 31,304 shares of common stock from employees in connection with payment of minimum tax withholding obligations relating to the lapse of restrictions on certain restricted stock awards during the three months ended March 31, 2012.
- (2) In November 2011, we announced that our Board of Directors authorized us to repurchase up to an aggregate of \$25.0 million in shares of our common stock under our stock repurchase program. Any shares of common stock repurchased under this program will no longer be deemed outstanding upon repurchase and will be returned to the pool of authorized shares. This repurchase program will expire on November 8, 2013 unless extended by our Board of Directors.

**ITEM 3. Defaults Upon Senior Securities**

None.

**ITEM 4. Mine Safety Disclosures**

Not applicable.

**ITEM 5. Other Information**

None.

**ITEM 6. Exhibits**



**Table of Contents**

**Exhibit**

**Number**

|         |  |
|---------|--|
| 3.1     | Restated Certificate of Incorporation of Quidel Corporation. (Incorporated by reference to Exhibit 3.1 to the Registrant's Quarterly Report on Form 10-Q filed on October 29, 2010.)                                 |
| 3.2     | Amended and Restated Bylaws of Quidel Corporation. (Incorporated by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K filed on November 8, 2000.)  |
| 4.1     | Certificate of Designations of Series C Junior Participating Preferred Stock. (Incorporated by reference to Exhibit 4.1 to the Registrant's Quarterly Report on Form 10-Q filed on October 29, 2010.)                |
| 10.1(1) | 2011 Cash Bonus Awards to the Registrant's Executive Officers. (Incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed on March 2, 2012.)                                    |
| 10.2(1) | 2012 Cash Incentive Compensation Plan for Registrant. (Incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed on March 6, 2012.)   |
| 10.3(1) | 2012 Employee Deferred Bonus Compensation Program for Registrant. (Incorporated by reference to Exhibit 10.2 to the Registrant's Current Report on Form 8-K filed on March 6, 2012.)                                 |
| 10.4(1) | 2012 Equity Incentive Plan Grants to Registrant's Executive Officers. (Incorporated by reference to Exhibit 10.3 to the Registrant's Current Report on Form 8-K filed on March 6, 2012.)                             |
| 10.5(1) | 2012 Annual Base Salaries for Registrant's Executive Officers, effective as of March 5, 2012. (Incorporated by reference to Exhibit 10.4 to the Registrant's Current Report on Form 8-K filed on March 6, 2012.)     |
| 31.1*   | Certification by Principal Executive Officer of Registrant pursuant to Rules 13a-14 and 15d-14, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.  |
| 31.2*   | Certification by Principal Financial and Accounting Officer of Registrant pursuant to Rules 13a-14 and 15d-14, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.                                 |
| 32.1*   | Certifications by Principal Executive Officer and Principal Financial and Accounting Officer of Registrant pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 101**   | XBRL Instance Document   |
| 101**   | XBRL Taxonomy Extension Schema Document  |
| 101**   | XBRL Taxonomy Calculation Linkbase Document  |
| 101**   | XBRL Taxonomy Label Linkbase Document  |
| 101**   | XBRL Taxonomy Presentation Linkbase Document   |

\* Filed herewith.

\*\* Pursuant to applicable securities laws and regulations, we are deemed to have complied with the reporting obligation relating to the submission of interactive data files in such exhibits and are not subject to liability under any anti-fraud provisions of the federal securities laws as long as we have made a good faith attempt to comply with the submission requirements and promptly amend the interactive data files after becoming aware that the interactive data files fail to comply with the submission requirements. Users of this data are advised that, pursuant to Rule 406T, these interactive data files are deemed not filed and otherwise are not subject to liability.

(1) Indicates a management plan or compensatory plan or arrangement.

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: April 27, 2012

**QUIDEL CORPORATION**

/s/ DOUGLAS C. BRYANT  
Douglas C. Bryant  
*President and Chief Executive Officer*

*(Principal Executive Officer)*

/s/ RANDALL J. STEWARD  
Randall J. Steward  
*Chief Financial Officer*

*(Principal Financial Officer and Accounting Officer)*

**Table of Contents**

**Exhibit Index**

**Exhibit Number**

|         |  |
|---------|--|
| 3.1     | Restated Certificate of Incorporation of Quidel Corporation. (Incorporated by reference to Exhibit 3.1 to the Registrant's Quarterly Report on Form 10-Q filed on October 29, 2010.)                                 |
| 3.2     | Amended and Restated Bylaws of Quidel Corporation. (Incorporated by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K filed on November 8, 2000.)  |
| 4.1     | Certificate of Designations of Series C Junior Participating Preferred Stock. (Incorporated by reference to Exhibit 4.1 to the Registrant's Quarterly Report on Form 10-Q filed on October 29, 2010.)                |
| 10.1(1) | 2011 Cash Bonus Awards to the Registrant's Executive Officers. (Incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed on March 2, 2012.)                                    |
| 10.2(1) | 2012 Cash Incentive Compensation Plan for Registrant. (Incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed on March 6, 2012.)   |
| 10.3(1) | 2012 Employee Deferred Bonus Compensation Program for Registrant. (Incorporated by reference to Exhibit 10.2 to the Registrant's Current Report on Form 8-K filed on March 6, 2012.)                                 |
| 10.4(1) | 2012 Equity Incentive Plan Grants to Registrant's Executive Officers. (Incorporated by reference to Exhibit 10.3 to the Registrant's Current Report on Form 8-K filed on March 6, 2012.)                             |
| 10.5(1) | 2012 Annual Base Salaries for Registrant's Executive Officers, effective as of March 5, 2012. (Incorporated by reference to Exhibit 10.4 to the Registrant's Current Report on Form 8-K filed on March 6, 2012.)     |
| 31.1*   | Certification by Principal Executive Officer of Registrant pursuant to Rules 13a-14 and 15d-14, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.  |
| 31.2*   | Certification by Principal Financial and Accounting Officer of Registrant pursuant to Rules 13a-14 and 15d-14, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.                                 |
| 32.1*   | Certifications by Principal Executive Officer and Principal Financial and Accounting Officer of Registrant pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 101**   | XBRL Instance Document   |
| 101**   | XBRL Taxonomy Extension Schema Document  |
| 101**   | XBRL Taxonomy Calculation Linkbase Document  |
| 101**   | XBRL Taxonomy Label Linkbase Document  |
| 101**   | XBRL Taxonomy Presentation Linkbase Document   |

\* Filed herewith.

\*\* Pursuant to applicable securities laws and regulations, we are deemed to have complied with the reporting obligation relating to the submission of interactive data files in such exhibits and are not subject to liability under any anti-fraud provisions of the federal securities laws as long as we have made a good faith attempt to comply with the submission requirements and promptly amend the interactive data files after becoming aware that the interactive data files fail to

**Table of Contents**

comply with the submission requirements. Users of this data are advised that, pursuant to Rule 406T, these interactive data files are deemed not filed and otherwise are not subject to liability.

- (1) Indicates a management plan or compensatory plan or arrangement.